Multi-institutional retrospective observational study of effectiveness and safety of treatment with Nivolmab for advanced or recurrent non-small cell lung cancer harboring EGFR mutation.
Phase of Trial: Phase IV
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2017 New trial record